Ethacridine’s predicted targets include MyD88, NF-κB, and MAPKs, suggesting it could temper TLR/NLR signaling to a moderate level—enough for infection control but not so much as to cause collateral tissue damage. This evidence concerns the gene NFKB1 and infection.